Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2009 - 2021)

Vertex Pharmaceuticals has reported Long-Term Debt Issuances for 9 years, with the latest figure at $10.0 million in Q4 2021.

• For the quarter ending Q4 2021, Long-Term Debt Issuances rose 114.68% year-over-year to $10.0 million; the trailing twelve-month figure through Sep 2022 stood at $10.0 million (down 42.06% YoY), and the FY2021 full-year result was $22.6 million, up 69.92% from the prior year.
• Long-Term Debt Issuances for Q4 2021 stood at $10.0 million, up from $1.0 million in the prior quarter.
• The five-year high for Long-Term Debt Issuances was $30.0 million in Q4 2017, with the low at $1.0 million in Q3 2021.
• Average Long-Term Debt Issuances over 5 years is $7.2 million, with a median of $5.3 million recorded in 2017.
• Year-over-year, Long-Term Debt Issuances sank 73.78% in 2018 and surged 114.68% in 2021.
• Tracing VRTX's Long-Term Debt Issuances over 5 years: stood at $30.0 million in 2017, then slumped by 73.78% to $7.9 million in 2018, then rose by 14.52% to $9.0 million in 2019, then tumbled by 48.23% to $4.7 million in 2020, then surged by 114.68% to $10.0 million in 2021.
• The last three Long-Term Debt Issuances figures came in at $10.0 million (Q4 2021), $1.0 million (Q3 2021), and $8.0 million (Q2 2021), per Business Quant data.

Peer Comparison